CN101993940A - In-situ hybridization detection kit for CHIP genes and detection method and application thereof - Google Patents
In-situ hybridization detection kit for CHIP genes and detection method and application thereof Download PDFInfo
- Publication number
- CN101993940A CN101993940A CN 200910056177 CN200910056177A CN101993940A CN 101993940 A CN101993940 A CN 101993940A CN 200910056177 CN200910056177 CN 200910056177 CN 200910056177 A CN200910056177 A CN 200910056177A CN 101993940 A CN101993940 A CN 101993940A
- Authority
- CN
- China
- Prior art keywords
- hybridization
- marker
- chip
- detection
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to an in-situ hybridization detection kit for CHIP genes, which comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is expressed as SEQ ID No.1. The invention also provides an in-situ hybridization detection method for the CHIP genes. In addition, the invention also provides application of the kit in preparing a medicament for detecting breast cancer diseases. The kit provided by the invention has the advantages of high sensitivity and strong specificity. The detection method is convenient and simple in operation, and can be universally used and popularized in hospitals of above district level.
Description
[technical field]
The present invention relates to a kind of test kit, specifically about a kind of hybridization in situ detection kit and detection method and application of CHIP gene
[background technology]
Mammary cancer is one of modal malignant tumour of women, and according to statistics, sickness rate accounts for the 7-10% of the various malignant tumours of whole body, is only second to uterus carcinoma the women.Its morbidity is normal relevant with heredity, and between 40-60 year, climacteric, women's sickness rate of front and back was higher.Only the mammary gland patient of about 1-2% is the male sex.Usually occur in the malignant tumour of breast glandular epithelium tissue.Be one of a kind of women's of having a strong impact on physical and mental health even life-threatening modal malignant tumour,
Mammary cancer changes to the formation cancer before cancer, need several years, how to accomplish early detection, diagnosis, prognosis detection and the recurrence after the diagnosis and treatment, shift that to detect in early days be the key that reduces M ﹠ M.
Research group of Japan University of tsukuba finds that the protein in the human body cell " CHIP " can suppress breast cancer cell propagation and shift.This achievement was published on Britain's " nature-cytobiology " (Nature Cell Biology) magazine network edition February 9.The researchist says that they notice that in human body cell, the level of protein " CHIP " reduces along with the development of mammary cancer, further discovers with experimental mouse, reduces the amount of " CHIP ", and the experimental mouse breast cancer cell forms the bulk tumour, and shifts and accelerate; Increase the amount of " CHIP ", breast cancer cell propagation and transfer ability then are subjected to great inhibition.The researchist says that this discovery shows, can or impel it to enliven propagation and the transfer that suppresses breast cancer cell by raising " CHIP " proteinic amount.This achievement provides thinking for exploitation prevents and treats the mammary cancer new drug.In addition, because " CHIP " protein also is present in mammary gland tissue in addition, the researchist infers that its may can also suppress the propagation and the transfer of other cancer cell.
Along with molecular biotechnology is perfect day by day, functional genomics, the deep expansion of research such as cancer genomics, so far, we might do more accurate early diagnosis on gene level, just can accomplish the early prediction diagnosis in canceration early stage or cancer cells formation (during mono-clonal).The present invention adopts nucleic acid hybridization in situ technology for detection CHIP expression of gene amount, and the early diagnosis of the gene level of mammary cancer is had very important clinical value.CHIP gene order number: NM-005861,1646bp, CDS:412 ... 1323bp is at karyomit(e) 16p13.3 ".
Hybridization in situ technique of the present invention (in situ hybridization) combines molecular biology and cytochemistry technology, is probe with the nucleic acid molecule of mark, in the technology of histocyte in situ detection specific nucleic acid molecule.Its principle is to make the nucleic acid strand (being probe) that contains distinguished sequence, process mark, under optimum conditions with histocyte in the complementary nucleic acid strand be that target nucleic acid is hybridized, with radioautograph or immunocytochemistry label probe is surveyed again, thereby shown special DNA or RNA molecule at cell in-situ.
[summary of the invention]
The objective of the invention is provides a kind of purposes of hybridization in situ detection kit of CHIP gene at deficiency of the prior art.
One purpose more of the present invention is that a kind of hybridization in situ detection kit of CHIP gene is provided.
Another purpose of the present invention is that a kind of in situ hybridization detection method of CHIP gene is provided.
For achieving the above object, the technical scheme taked of the present invention is:
The application of a kind of hybridization in situ detection kit of CHIP gene in preparation detection breast cancer disease medicine, described test kit comprises hybridization probe, marker, described hybridization probe sequence is shown in SEQ ID NO.1.
The RNA sequence of described hybridization probe sequence shown in SEQ ID NO.1.
Described marker is selected from radionuclide or non-radioactive marker.
Described radionuclide is selected from
3H,
35S,
125I or
32A kind of among the P.
Described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.
Described non-radioactive marker is preferably from digoxin.
Described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.
For realizing above-mentioned second purpose, the technical scheme that the present invention takes is:
A kind of hybridization in situ detection kit of CHIP gene comprises hybridization probe, marker, and wherein said hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.
For realizing above-mentioned the 3rd purpose, the technical scheme that the present invention takes is:
A kind of in situ hybridization detection method of CHIP gene, this method may further comprise the steps:
A, the hybridization probe in the test kit is contacted with RNA to be measured in the substrate, form hybridization complex;
The hybridization complex that b, detection a step obtain.
The component of diagnostic kit of the present invention is by hybridization probe, hybridization solution, developer, compositions such as synergistic agent.The nucleic acid hybridization principle of this test kit is that the molecular biology insider all knows, and the concrete operations step is to carry out quantitative analysis, result's report under sample disposal, prehybridization, hybridization, immunohistochemical staining, the mirror, and wherein Za Jiao concrete steps comprise:
Instrumentation:
1). sample to be measured is put into reactive tank;
2). instrument discards liquid automatically, adds Digestive system automatically;
3). instrument discards liquid automatically, and the back is fixing automatically;
4). instrument discards liquid automatically, automatically prehybridization (42 ℃);
5). instrument discards liquid automatically, cleans automatically;
6). instrument discards liquid automatically, automatically hybridization (42 ℃);
7). instrument discards liquid automatically, cleans automatically;
8). instrument discards liquid automatically, and automatic and DIG antibody is cultivated (room temperature);
9). instrument discards liquid automatically, cleans colour developing automatically;
10). take out the mounting microscopy.
The invention has the advantages that:
1, test kit provided by the invention has characteristics highly sensitive, high specificity.
2, detection method of the present invention is convenient and simple for operation, can be widely used and promoted in Municipal Hospitals.
3, clinical meaning of the present invention is that more early stage tracking detects mammary cancer generation dynamic process, and the detection and the screening implement that are used for the mammary cancer preventive medicine.Diagnostic kit of the present invention is with other detects the oncofetal protein mark clinically, and the medical imaging inspection has remarkable difference.The present invention can detect the CHIP unconventionality expression on gene level, before medical imaging inspection and other inspection is not found occupancy mammary cancer focus, before the cancer biochemical indicator does not produce unusually, also do not form before the lump, can accomplish the information acquisition of above abnormal gene expression early, give real prognosis early diagnosis of clinical mammary cancer sufferer.So just might implement early diagnosis, early prevention, the early treatment of mammary cancer, might from the source, thoroughly effect a radical cure the mammary cancer foul disease.
[description of drawings]
Fig. 1 is a mammary gland cancer patient CHIP genetic expression picture in the embodiment of the invention.
Fig. 2 is a normal breast CHIP genetic expression picture.
[embodiment]
Below in conjunction with accompanying drawing the specific embodiment of the invention is elaborated.
Embodiment 1
A kind of hybridization in situ detection kit of CHIP gene comprises hybridization probe, marker, synergistic agent, and wherein, described hybridization probe sequence is shown in SEQ ID NO.1.The hybridization probe digoxigenin labeled.Other liquid and sample in the test kit are composed as follows:
Digestive system 100 μ l/ manage 1 pipe/box colourless transparent liquid
Protection liquid 100 μ l/ pipe 1 pipe/box colourless transparent liquid
Prehybridization solution 1300 μ l/ manage 2 pipe/box colourless transparent liquids
Justice hybridization solution 10 μ l/ pipe 1 pipe/box colourless transparent liquid
Antisense hybridization solution 10 μ l/ manage 1 pipe/box colourless transparent liquid
Confining liquid 1000 μ l/ manage 1 pipe/box colourless transparent liquid
Alkaline phosphatase enzyme antibody 1 μ l/ manages 1 pipe/box colourless transparent liquid
Developer A 175 μ l/ manage 1 pipe/box yellow liquid
Developer B 320 μ l/ manage 1 pipe/box colourless transparent liquid
Light yellow or the colourless transparent liquid of damping fluid I 10x 90ml/ bottle 1 bottle/box
Light yellow or the colourless transparent liquid of damping fluid II 10x 80ml/ bottle 1 bottle/box
Light yellow or the colourless transparent liquid of damping fluid III 10x 20m/ bottle 3 bottle/boxes
Light yellow or the colourless transparent liquid of damping fluid IV 10x 90ml/ bottle 1 bottle/box
Stationary liquid 90ml/ bottle 1 bottle/box colourless transparent liquid
6/box of positive control sample
Mentioned reagent composition explanation: (all reagent are available from SIGMA)
1, Digestive system: the 20mg/ml Proteinase K, the 100mg Proteinase K adds DEPC-H
2O 5ml;
2, the glycine of protection liquid: 0.2g adds 1 * damping fluid I of 1ml;
3, prehybridization solution: 1 * damping fluid II 7.5ml
50×D?3ml
10mg/ml?yest?t-RNA?750ul
11mg/ml?SALMON?TESTES?DNA 682ul
0.04M?EDTA?3ml
50％formamide?15ml
4, the bloking of confining liquid: 0.03g (buying from Roche Holding Ag) adds 1ml 1 * damping fluid III;
5,10x damping fluid I:(PH7.1-7.4)
NaCl?80g
Na
2HPO
4.12H
2O 360g
KCl 2g
KH
2PO
42g
Add tri-distilled water to 1l, and autoclaving;
6,10x damping fluid II:(PH7.0)
NaCl 175.3g
Trisodium Citrate 88.2g
Several of HCl
Add tri-distilled water to 1l, and autoclaving;
7, damping fluid III:(PH7.9)
Tris 121.1g
NaCl 87.66g
About HCl 60ml
Add tri-distilled water to 1l, and autoclaving;
8, damping fluid IV:
1M Tris-HCl (PH9.5): Tirs 121.1g adds about HCl 3ml, adds water 900ml, transfers PH to 9.5, adds water to 1l, and autoclaving;
1M NaCl:NaCl 58.44 adds water to 1l, and autoclaving;
0.5M MgCl
2: 101.65g MgCl
2.6H
2O adds water to 1l, and autoclaving;
9, stationary liquid: Paraformaldehyde 96 40g adds 1 * damping fluid I to 1l, and heat (about 50-60 degree) is stirred to dissolving a little;
10, developer A:NBT 1g adds 70%DMF11.44ml;
11, developer B:BCIP 1g adds 100%DMF30ml.
Test kit of the present invention can many person-portions use or person-portion use.
Embodiment 2
A kind of CHIP gene hybridization in situ detection method and test kit thereof are used
One, sample disposal
1, with the centrifuge tube of 10ml, dress 4.5ml lymphocyte separation medium, again the 3ml anticoagulation is slowly added contain lymphocyte separation medium (blood: in centrifuge tube lymphocyte separation medium=1: 1.5), the centrifugal 10min of 2000r/min;
2, draw the middle layer white corpuscle to another centrifuge tube, in this pipe, add 1 * damping fluid I of about twice again, mixing, the centrifugal 10min of 1500g/min;
3, abandon supernatant. precipitation adds 1 * damping fluid I of about twice, mixing, the centrifugal 10min of 1500g/min;
4, abandon supernatant, and test tube mouth excess liquid is gone with the tissue suction.Again precipitation is made suspension, drop in push jack on the slide, seasoning.(hospital with good conditionsi can use the pelleter film-making.) 3ml blood, can do 4 slice, thin pieces;
5, with 40ml 4% stationary liquid, in glass jar, fixedly 30min uses 1 * damping fluid I to wash 5min again.Every cylinder can be put 16;
6, sample can be kept at-20 ℃, or continues to do experiment.
Two, reagent in the test kit is mixed with working concentration
1, with 10 * damping fluid I with tri-distilled water by being diluted to 1 * damping fluid I at 1: 10;
2, with 20 * damping fluid II with tri-distilled water by being diluted to 2 * damping fluid II at 1: 10;
By being diluted to 0.2 * damping fluid II at 1: 100; By being diluted to 0.1 * damping fluid II at 1: 200;
3, with 10 * damping fluid III with tri-distilled water by being diluted to 1 * damping fluid III at 1: 10;
4,10 * damping fluid IV with tri-distilled water by be diluted at 1: 10 * damping fluid IV (get 1#, 2#, each 10ml of 3#, add water to 100ml both can).
Three, experimental procedure:
1, gets two of every person's samples to be checked, two of (other two give over to check with) and positive control samples (test at every turn and do a pair of positive control);
2, in glass jar, add Digestive system (Digestive system 100ul adds 1 * damping fluid 199.9ml, is working concentration) 20ml.37 ℃ of water-bath preheatings 10 minutes.Put 16 slides into, handle 12min, use 1 * damping fluid I to wash 5min again for 37 ℃;
3, wash 10min with 0.2% protection liquid (protection liquid 1ml adds 1 * damping fluid I99ml and is working concentration), tri-distilled water is washed 5min, and above process is all carried out at glass jar.The slide seasoning;
4, slide is put into the box of preserving moisture, add prehybridization solution 20ul/ sheet. covered, the lid box of tightly preserving moisture is placed in 42 ℃ of constant water bath box more than the 3h;
5, take out slide, discard cover glass, slide is put into glass jar, with 70%, 90%, 95% ethanol is respectively washed 2min, seasoning;
6, slide is put into the box of preserving moisture, two of every patient specimens, one adds just hybridization solution 20ul/ sheet, and another adds antisense hybridization solution 20ul/ sheet, covered, the lid box of tightly preserving moisture is placed on 16-24h in 42 ℃ of constant water bath box;
7, take out slide, discard cover glass, slide is put into glass jar
In 42 ℃ of constant water bath box, wash twice, each 15min with 2 * damping fluid II
In 42 ℃ of constant water bath box, wash once each 15min with 0.2 * damping fluid II
In 42 ℃ of constant water bath box, wash twice, each 15min with 0.1 * damping fluid II;
8, wash 30s with 1 * damping fluid III, take out slide, seasoning;
9, slide is put into the box of preserving moisture, add 0.5%l confining liquid (the 1ml confining liquid adds 5ml1 * damping fluid III)
The 100ul/ sheet covers the box of tightly preserving moisture, and at room temperature acts on 30min;
10, take out slide, III washes 30s with 1 * damping fluid, seasoning;
11, slide is put into the box of preserving moisture, add alkaline phosphatase enzyme antibody (adding 1.8ml 1 * damping fluid III) 100ul/ sheet, cover the box of tightly preserving moisture and at room temperature act on 30min;
12, take out slide, wash 3 times, each 15min with 1 * damping fluid III;
13,1 * damping fluid IV washes 2min, adds developer (developer A73.3ul, developer B157.5ul are added among 30ml 1 * damping fluid IV, mixing), more than the room temperature lucifuge 12h;
14, wash 5min with tri-distilled water, seasoning, (add with glycerine 10% 1 * damping fluid I mixing) mounting microscopy.
Four, the result judges
100-300 cell of counting calculates the per-cent of catching the purple cell under light microscopic.
What the positive control sample added the antisense hybridization solution should catch purple more than 80%.
All add the negative internal reference of just hybridization solution should be colourless.
The cDNA of digoxigenin labeled, RNA and oligonucleotide probe, not only probe has a biotin labeling advantage, also having overcome biotin labeled probe is organized the endogenous vitamin H to do shortcomings such as sorrow in the crossover process in position), this hybridization probe and the leukocytic RNA nucleic acid to be measured of blood of human body are hybridized, method with immunohistochemical methods develops the color again, under light microscopic, observe existence and the location of mRNA,, judge the expression amount of goal gene according to painted cell count.
The inventive method is a nucleic acid hybridization in situ technology commonly used at present, and this method is used for determining the prognosis of mammary cancer by detecting the CHIP gene expression amount in the substrate cell.Clinical study shows, the CHIP gene is low the expression in mammary cancer, because the CHIP gene is at normal people's high expression level, and the low expression explanation mammary cancer of CHIP gene, CHIP expression of gene degree is relevant with the prognosis of breast cancer, belongs to negative correlation, expresses that more to hang down prognosis poorer.Thereby obtain the diagnostic message of mammary cancer.As mentioned above, when detecting CHIP genetic expression, measurable experimenter is the mammary cancer situation.Concrete outcome is asked for an interview Fig. 1 and Fig. 2.
SEQUENCE?LISTING
＜110〉Rui bends biotechnology (Shanghai) Co., Ltd.
＜120〉a kind of hybridization in situ detection kit of CHIP gene and detection method thereof and application
<130>/
<160>1
<170>PatentIn?version?3.3
<210>1
<211>1646
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>1
gctgttgcgg?gagcgcgccc?tcagcgaagc?aagtgaggca?tctcactggg?aaagtcgaat 60
gtgtgtggcg?gccgccgccg?aggcgggttc?cgaagagacc?tcagcagggc?aggccagggc 120
ctacgcgaac?gcccaccctt?aagagcgcgg?ggacagggaa?ctggagcgtt?cctcccagcc 180
cccgacgtcg?cgggcccagt?gtccccgtcc?aggctggttg?ggcgcacgcg?cggccccact 240
cgcccccacg?cgtgcgtccc?cgctggtccc?gcccccggcc?ggaagttccg?gcggcggagc 300
tgggccgggc?ccgagcggat?cgcgggctcg?ggctgcgggg?ctccggctgc?gggcgctggg 360
ccgcgaggcg?cggagcttgg?gagcggagcc?caggccgtgc?cgcgcggcgc?catgaagggc 420
aaggaggaga?aggagggcgg?cgcacggctg?ggcgctggcg?gcggaagccc?cgagaagagc 480
ccgagcgcgc?aggagctcaa?ggagcagggc?aatcgtctgt?tcgtgggccg?aaagtacccg 540
gaggcggcgg?cctgctacgg?ccgcgcgatc?acccggaacc?cgctggtggc?cgtgtattac 600
accaaccggg?ccttgtgcta?cctgaagatg?cagcagcacg?agcaggccct?ggccgactgc 660
cggcgcgccc?tggagctgga?cgggcagtct?gtgaaggcgc?acttcttcct?ggggcagtgc 720
cagctggaga?tggagagcta?tgatgaggcc?atcgccaatc?tgcagcgagc?ttacagcctg 780
gccaaggagc?agcggctgaa?cttcggggac?gacatcccca?gcgctcttcg?aatcgcgaag 840
aagaagcgct?ggaacagcat?tgaggagcgg?cgcatccacc?aggagagcga?gctgcactcc 900
tacctctcca?ggctcattgc?cgcggagcgt?gagagggagc?tggaagagtg?ccagcgaaac 960
cacgagggtg?atgaggacga?cagccacgtc?cgggcccagc?aggcctgcat?tgaggccaag 1020
cacgacaagt?acatggcgga?catggacgag?cttttttctc?aggtggatga?gaagaggaag 1080
aagcgagaca?tccccgacta?cctgtgtggc?aagatcagct?ttgagctgat?gcgggagccg 1140
tgcatcacgc?ccagtggcat?cacctacgac?cgcaaggaca?tcgaggagca?cctgcagcgt 1200
gtgggtcatt?ttgaccccgt?gacccggagc?cccctgaccc?aggaacagct?catccccaac 1260
ttggctatga?aggaggttat?tgacgcattc?atctctgaga?atggctgggt?ggaggactac 1320
tgaggttccc?tgccctacct?ggcgtcctgg?tccaggggag?ccctgggcag?aagcccccgg 1380
cccctataca?tagtttatgt?tcctggccac?cccgaccgct?tcccccaagt?tctgctgttg 1440
gactctggac?tgtttcccct?ctcagcatcg?cttttgctgg?gccgtgatcg?tccccctttg 1500
tgggctggaa?aagcaggtga?gggtgggctg?ggctgaggcc?attgccgcca?ctatctgtgt 1560
aataaaatcc?gtgagcacga?ggtgggacgt?gctggtgtgt?gaaaaaaaaa?aaaaaaaaaa 1620
aaaaaaaaaa?aaaaaaaaaaaaaaaa 1646
Claims (10)
1. the application of the hybridization in situ detection kit of a CHIP gene in preparation detection breast cancer disease medicine, described test kit comprises hybridization probe, marker, described hybridization probe sequence is shown in SEQ ID NO.1.
2. application according to claim 1 is characterized in that: the RNA sequence of described hybridization probe sequence shown in SEQ ID NO.1.
3. application according to claim 1 and 2 is characterized in that: described marker is selected from radionuclide or non-radioactive marker.
4. application according to claim 3 is characterized in that: described radionuclide is selected from
3H,
35S,
125I or
32A kind of among the P.
5. application according to claim 3 is characterized in that: described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.
6. application according to claim 5 is characterized in that: described non-radioactive marker is preferably from digoxin.
7. application according to claim 1 and 2 is characterized in that: described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.
8. the hybridization in situ detection kit of a CHIP gene comprises hybridization probe, marker, it is characterized in that, described hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.
9. the in situ hybridization detection method of a CHIP gene is characterized in that, this method may further comprise the steps:
A, the hybridization probe in the described test kit of claim 8 is contacted with RNA to be measured in the substrate, form hybridization complex;
The hybridization complex that b, detection a step obtain.
10. detection method according to claim 9 is characterized in that: the condition that forms hybridization complex in a step is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour, and described substrate is selected blood cell sample or histocyte sample for use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910056177 CN101993940A (en) | 2009-08-10 | 2009-08-10 | In-situ hybridization detection kit for CHIP genes and detection method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910056177 CN101993940A (en) | 2009-08-10 | 2009-08-10 | In-situ hybridization detection kit for CHIP genes and detection method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101993940A true CN101993940A (en) | 2011-03-30 |
Family
ID=43784689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910056177 Pending CN101993940A (en) | 2009-08-10 | 2009-08-10 | In-situ hybridization detection kit for CHIP genes and detection method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101993940A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104513822A (en) * | 2013-09-30 | 2015-04-15 | 深圳华大基因科技有限公司 | STUB1 gene mutant and application thereof |
-
2009
- 2009-08-10 CN CN 200910056177 patent/CN101993940A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104513822A (en) * | 2013-09-30 | 2015-04-15 | 深圳华大基因科技有限公司 | STUB1 gene mutant and application thereof |
| CN104513822B (en) * | 2013-09-30 | 2017-12-19 | 深圳华大基因股份有限公司 | STUB1 gene mutation bodies and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101993941A (en) | In situ hybridization detection kit of CD44 gene and detection method and application thereof | |
| CN101993940A (en) | In-situ hybridization detection kit for CHIP genes and detection method and application thereof | |
| CN101363046A (en) | Kit for broad spectrum cancer hybridization in situ, detection method and application thereof | |
| CN101363050B (en) | Kit for CD326 gene hybridization in situ, detection method and application thereof | |
| CN101993937A (en) | Maspin gene in-situ hybridization detection kit and detection method and use thereof | |
| CN101386888B (en) | Kit forEvi-1 gene hybridization in situ | |
| CN101993935A (en) | In-situ hybridization assay kit and detection method for MTDH gene and application of kit | |
| CN101469352B (en) | In situ hybridization detection kit for early uterocarcinoma | |
| CN101429542A (en) | Hybridization in situ detection kit for VMP1 gene, detection method and uses thereof | |
| CN101469349A (en) | In situ hybridization detection kit for lung cancer , detecting method and use thereof | |
| CN101988101A (en) | In-situ hybridization detection kit of MK gene as well as detection method and application thereof | |
| CN101993942A (en) | In situ hybridization detection kit for cancer antigen 15-3 (CA15-3) genes, detection method and application thereof | |
| CN101988113A (en) | In-situ hybridization detection kit for DCC genes and detection method and application thereof | |
| CN101851668A (en) | In situ hybridization detection kit of AP-1 gene, and detection method and application thereof | |
| CN101328499B (en) | In situ hybridization detection reagent box of RhoGDI2 gene, detection method and use thereof | |
| CN101993919A (en) | In-situ hybridization detection kit for PD-ECGF genes and detection method and application thereof | |
| CN101993934A (en) | In situ hybridization detection kit for EZH2 gene, detection method and application thereof | |
| CN101988117A (en) | In-situ hybridization detection reagent kit of CA242 gene, detection method and application thereof | |
| CN101993917A (en) | Cdc2 gene in-situ hybridization detection kit and detection method and use thereof | |
| CN101363049A (en) | Kit for early cancer metastasis hybridization in situ, detection method and application thereof | |
| CN101363053A (en) | Kit for tMK gene hybridization in situ, detection method and application thereof | |
| CN101993930A (en) | In situ hybridization detection kit for bc1-2 genes, detection method and application thereof | |
| CN101993915A (en) | In situ hybridization detection kit for Heparinase gene, detection method and application thereof | |
| CN101993932A (en) | In situ hybridization detection kit and detection method for MDA-7 gene and application | |
| CN101988111A (en) | In-situ hybridization detection kit of CA50 (cancer antigen) gene as well as detection method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SUZHOU FUYING GENE TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: RUIQU BIOTECHNOLOGY (SHANGHAI) CO., LTD. Effective date: 20110429 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201108 ROOM 426, BUILDING 4, NO. 728, GUANGHUA ROAD, MINHANG DISTRICT, SHANGHAI TO: 215132 ROOM 307, BUILDING A2, BIOBAY, NO. 218, XINGHU STREET, SUZHOU INDUSTRIAL PARK |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110429 Address after: 215132 Suzhou Industrial Park BioBAY Xinghu Street No. 218 building A2 room 307 Applicant after: Suzhou Fuying Gene Technology Co.,Ltd. Address before: 201108 room 4, building 728, Guanghua Road, 426, Shanghai, Minhang District Applicant before: Ruiqu Biotechnology (Shanghai) Co., Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110330 |